AIM (AIM ImmunoTech) FCF Margin %: -12,518.18% (As of Mar. 2026)


AIM AIM ImmunoTech Inc AIM
33 GF Score
Price $0.31
GF Value $2.69
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is AIM ImmunoTech FCF Margin %?

AIM ImmunoTech AIM -12.18% 33 FCF Margin % is -12,518.18% as of Mar. 2026. GuruFocus rates AIM with a GF Score™ of 33/100 and a GF Value™ of $2.69 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 958 Biotechnology companies, AIM ImmunoTech ranks worse than 94.26% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. AIM ImmunoTech's Free Cash Flow for the three months ended in Mar. 2026 was $-2.75 Mil. AIM ImmunoTech's Revenue for the three months ended in Mar. 2026 was $0.02 Mil. Therefore, AIM ImmunoTech's FCF Margin % for the quarter that ended in Mar. 2026 was -12,518.18%.

As of today, AIM ImmunoTech's current FCF Yield % is -134.89%.

The historical rank and industry rank for AIM ImmunoTech's FCF Margin % or its related term are showing as below:

AIM' s FCF Margin % Range Over the Past 10 Years
Min: -12880.68   Med: -8799.97   Max: -1832.95
Current: -12417.02

During the past 13 years, the highest FCF Margin % of AIM ImmunoTech was -1832.95%. The lowest was -12880.68%. And the median was -8799.97%.

AIM's FCF Margin % is ranked worse than
94.26% of 958 companies
in the Biotechnology industry
Industry Median: -85.21 vs AIM: -12417.02

AIM ImmunoTech FCF Margin % Related Terms

AIM ImmunoTech FCF Margin % Historical Data

* Premium members only.

The historical data trend for AIM ImmunoTech's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AIM ImmunoTech FCF Margin % Chart

AIM ImmunoTech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10,813.33 -11,616.31 -10,817.82 -9,084.71 -12,880.68

AIM ImmunoTech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15,106.25 -7,032.00 -19,534.62 -9,909.52 -12,518.18

AIM vs BGMS, FBLG, CLGN: FCF Margin % Comparison

For the Biotechnology subindustry, AIM ImmunoTech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AIM ImmunoTech FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's FCF Margin % distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's FCF Margin % falls into.


AIM
33GF Score
AIM ImmunoTech Inc AIM
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AIM ImmunoTech FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

AIM ImmunoTech's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-11.335/0.088
=-12,880.68 %

AIM ImmunoTech's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-2.754/0.022
=-12,518.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -12,518.18% mean?
AIM ImmunoTech (AIM) has a FCF Margin % of -12,518.18% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on AIM ImmunoTech and its competitors. According to the industry distribution chart, AIM ImmunoTech ranks #903 out of 958 companies in the Biotechnology industry, placing it in the top 94.3%.
Is AIM ImmunoTech's FCF Margin % too high?
AIM ImmunoTech's current FCF Margin % is -12,518.18%. Based on the distribution chart, AIM ImmunoTech ranks #903 out of 958 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, AIM ImmunoTech has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AIM ImmunoTech's FCF Margin % compare to BGMS and FBLG?
According to the Biotechnology industry distribution chart, AIM ImmunoTech ranks #903 out of 958 companies for FCF Margin %. This places AIM ImmunoTech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on AIM ImmunoTech and its competitors. AIM ImmunoTech's current FCF Margin % is -12,518.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AIM ImmunoTech stock overvalued right now?
Based on GuruFocus' analysis, AIM ImmunoTech (AIM) is currently considered Possible Value Trap. The stock's GF Value™ is $2.69, compared to a current price of $0.31 — trading 88.4% below its estimated fair value. The current FCF Margin % is -12,518.18%. AIM ImmunoTech's overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For AIM ImmunoTech (AIM), the current FCF Margin % is -12,518.18% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AIM ImmunoTech (AIM) Overvalued in 2026?

Based on GuruFocus' analysis, AIM ImmunoTech stock appears to be undervalued. The current stock price of $0.31 is trading 88.4% below its estimated GF Value™ of $2.69. GuruFocus considers AIM ImmunoTech to be Possible Value Trap.

Key valuation signals for AIM:

  • FCF Margin %: -12,518.18%
  • GF Value™: $2.69 vs. price of $0.31 (88.4% below fair value)
  • GF Score™: 33/100 with 6 warning signs

No single metric tells the full story. See the AIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AIM ImmunoTech Business Description

Other Exchanges 0A4Y:UK
Address 2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
33GF Score

Get the complete analysis for AIM

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.31
Price
$2.69
GF Value